Find Panobinostat lactate manufacturers, exporters & distributors on PharmaCompass

Panobinostat

panobinostat

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

2 API Suppliers, 1 USDMF, 2 EU WC, 1 NDC API, 1 Listed Suppliers

DEVELOPMENTS

5 Drug(s) in Development

5 Drug(s) in Development

DOSSIERs // Finished Dosage Formulations

3 Dossiers, 3 FDA Orange Book

DRUG PRODUCT COMPOSITION

CAPSULE;ORAL - EQ 10MG BASE, CAPSULE;ORAL - EQ 15MG BASE, CAPSULE;ORAL - EQ 20MG BASE

CAPSULE;ORAL - EQ 10MG BASE
CAPSULE;ORAL - EQ 15MG BASE
CAPSULE;ORAL - EQ 20MG BASE

RELATED EXCIPIENT COMPANIES

Suppliers, 16 SPI Pharma, 15 Roquette, 9 Microlex e.U, 8 Gangwal Healthcare, 8 Sigachi Industries, 6 Kerry, 4 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 3 Ingredion Pharma Solutions, 3 Gangwal Chemicals, 3 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 2 Vasa Pharmachem, 2 Prachin Chemical, 2 DFE Pharma, 1 Ideal Cures Pvt Ltd, 1 Pfanstiehl, 1 Pharmatrans-Sanaq, 1 DKSH, 1 Rochem International Inc, 1 Seppic, 1 Shijiazhuang Huaxu Pharmaceutical, 1 BASF

EXCIPIENTS BY APPLICATIONS

45 Fillers, Diluents & Binders, 24 Direct Compression, 14 Chewable & Orodispersible Aids, 13 Taste Masking, 12 Co-Processed Excipients, 11 Thickeners and Stabilizers, 10 Lubricants & Glidants, 9 Disintegrants & Superdisintegrants, 9 Granulation, 5 Controlled & Modified Release, 3 Coating Systems & Additives, 3 Parenteral, 1 Film Formers & Plasticizers, 1 API Stability Enhancers, 1 Rheology Modifiers, 1 Emulsifying Agents

GLOBAL SALES INFORMATION

7 US Medicaid Prescriptions

7 US Medicaid Prescriptions

PATENTS

6 US Patents

6 US Patents

DIGITAL CONTENT

1 Data Compilations & Company Tracker #PharmaFlow, 10 News

Product Search

API SUPPLIERS

API Suppliers

US DMFs Filed

CEP/COS Certifications

JDMFs Filed

Other Certificates

Other Suppliers

API REF. PRICE (USD / KG)

API Market Place

INTERMEDIATES

DOSSIERS // FDF

USA (Orange Book)

Europe

Canada

Australia

South Africa

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

52.00

Annual Reports

FDF Market Place

EXCIPIENTS

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

USP

Other Listed Suppliers

SERVICES

Also known as: 960055-56-5, Panobinostat lactate [jan], Panobinostat (lactate), Hn0t99oo4v, Panobinostat lactate anhydrous, Chebi:85991

Molecular Formula

C₂₄H₂₉N₃O₅

Molecular Weight

439.5 g/mol

InChI Key

XVDWNSFFSMWXJJ-ASTDGNLGSA-N

FDA UNII

HN0T99OO4V

Panobinostat Lactate is the lactate form of panobinostat, a pan histone deacetylase (HDAC) inhibitor, with potential antineoplastic activity. Upon administration, panobinostat selectively targets, binds to and inhibits HDAC, which induces hyperacetylation of core histone proteins. The accumulation of highly acetylated histones leads to chromatin remodeling, an altered pattern of gene expression, inhibition of tumor oncogene transcription and the selective transcription of tumor suppressor genes. This results in the inhibition of tumor cell division and the induction of tumor cell apoptosis. HDAC, upregulated in many tumor cell types, is an enzyme family that deacetylates histone proteins.

1 2D Structure

panobinostat

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide;2-hydroxypropanoic acid

2.1.2 InChI

InChI=1S/C21H23N3O2.C3H6O3/c1-15-18(19-4-2-3-5-20(19)23-15)12-13-22-14-17-8-6-16(7-9-17)10-11-21(25)24-26;1-2(4)3(5)6/h2-11,22-23,26H,12-14H2,1H3,(H,24,25);2,4H,1H3,(H,5,6)/b11-10+;

2.1.3 InChI Key

XVDWNSFFSMWXJJ-ASTDGNLGSA-N

2.1.4 Canonical SMILES

CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)C=CC(=O)NO.CC(C(=O)O)O

2.1.5 Isomeric SMILES

CC1=C(C2=CC=CC=C2N1)CCNCC3=CC=C(C=C3)/C=C/C(=O)NO.CC(C(=O)O)O

2.2 Other Identifiers

2.2.1 UNII

HN0T99OO4V

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. 960055-56-5

2. Panobinostat Lactate [jan]

3. Panobinostat (lactate)

4. Hn0t99oo4v

5. Panobinostat Lactate Anhydrous

6. Chebi:85991

7. 960055-56-5 (lactate)

8. (e)-n-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)acrylamide 2-hydroxypropanoate

9. Farydak (tn)

10. Panobinostat Lactate (jan)

11. (2e)-n-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino(methyl)phenyl)prop-2-enamide Mono((2rs)-2-hydroxypropanoate)

12. Propanoic Acid, 2-hydroxy-, Compd. With (2e)-n-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)-2-propenamide (1:1)

13. (2e)-n-hydroxy-3-[4-({[2-(2-methyl-1h-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide Lactic Acid

14. Unii-hn0t99oo4v

15. Propanoic Acid, 2-hydroxy-, Compd. With (2e)-n-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2-propenamide (1:1)

16. Panobinostat Dl-lactate

17. Schembl2315056

18. Schembl2315067

19. Chembl3545368

20. Dtxsid401026247

21. Bcp25197

22. Ex-a2659

23. Hy-10224a

24. Panobinostat Lactate [who-dd]

25. Panobinostat Lactate [orange Book]

26. Cs-0030991

27. D10019

28. A917191

29. Q27158837

30. (2e)-n-hydroxy-3-[4-({[2-(2-methyl-1h-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide; 2-hydroxypropanoic Acid

31. (e)-n-hydroxy-3-(4-(((2-(2-methyl-1h-indol-3-yl)ethyl)amino)methyl)phenyl)acrylamide2-hydroxypropanoate

32. (e)-n-hydroxy-3-[4-[[2-(2-methyl-1h-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide;2-hydroxypropanoic Acid

33. 2-hydroxypropanoic Acid--(2e)-n-hydroxy-3-[4-({[2-(2-methyl-1h-indol-3-yl)ethyl]amino}methyl)phenyl]prop-2-enamide (1/1)

34. N-({4-[(1e)-3-(hydroxyamino)-3-oxoprop-1-en-1-yl]phenyl}methyl)-2-(2-methyl-1h-indol-3-yl)ethan-1-aminium 2-hydroxypropanoate

35. N-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl) Ethyl]amino]methyl]phenyl]-2e-2-propenamide Dl-lactate Salt

36. N-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide Dl-lactate Salt

37. N-hydroxy-3-[4-[[[2-(2-methyl-1h-indol-3-yl)ethyl]amino]methyl]phenyl]-2e-2-propenamide Lactate Salt

2.4 Create Date

2008-02-11

3 Chemical and Physical Properties

Molecular Formula	C₂₄H₂₉N₃O₅
Molecular Weight	439.5 g/mol
Hydrogen Bond Donor Count	6
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	8
Exact Mass	439.21072103 g/mol
Monoisotopic Mass	439.21072103 g/mol
Topological Polar Surface Area	135 Å²
Heavy Atom Count	32
Formal Charge	0
Complexity	533
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	1
Defined Bond Stereocenter Count	1
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	2

4 Drug and Medication Information

4.1 Drug Indication

Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.

5 Pharmacology and Biochemistry

5.1 ATC Code

L01XH03